Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
주식 순위 #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
주가
$0.00047446
시가총액
$82.80
변동 (1일)
0.00%
변동 (1년)
-98.16%
국가
FR
거래 Neovacs S.A. (ALNEV)

카테고리

Neovacs S.A. (ALNEV)의 매출
Dec 2024 기준 매출 TTM: $303.12K
Neovacs S.A.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $303.12K입니다. 2023년에 회사는 $589.67K의 수익을 올렸으며 이는 2022년의 $1.19K 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Neovacs S.A.의 수익 기록 (2007 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $303.12K -20.48%
2024 $381.21K -35.35%
2023 $589.67K 49,335.08%
2022 $1.19K -95.36%
2021 $25.69K -29.17%
2020 $36.27K 0.00%
2019 0.00 -100.00%
2018 $166.63K 0.00%
2017 0.00 -100.00%
2016 $16.23K -89.89%
2015 $160.58K -6.42%
2014 $171.60K 317.73%
2013 $41.08K 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 -100.00%
2008 $75.78K -59.14%
2007 $185.43K 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$48.55B 16,015,729.38%
DK
$12.04B 3,971,340.03%
US
$14.34B 4,731,589.19%
US
$9.08B 2,996,119.45%
BE
$5.49B 1,811,461.99%
NL